BOOTS/HOECHST CELANESE TO COLLABORATE ON BULK IBUPROFEN production in the U.S. via a 50/50 joint venture, the companies announced in an April 21 press release. "The partners expect to install in the United States a commercial facility which will use Hoechst Celanese technology. The facility is expected to come on stream in 1991," the two companies said. An ibuprofen production line will be built in one of Hoechst Celanese's three existing manufacturing plants in Texas. The installation of the ibuprofen manufacturing line is expected to require capital costs of $ 35 mil., the companies noted. The new plant will have the capacity to produce 2,500 metric tons of bulk ibuprofen annually, Boots predicted. Boots, which discovered ibuprofen, currently supplies the worldwide market for bulk ibuprofen from a 3,000-ton-per-year facility in Nottingham, England, the company said. The Nottingham plant provides bulk ibuprofen to Boots Pharmaceuticals in Shreveport, Louisiana for the production of Rufen and to American Home Products for the manufacture of Advil. Boots used to supply Upjohn with bulk ibuprofen. Boots' primary competitor in the U.S. bulk ibuprofen market is Ethyl Corp., which is currently the only U.S. manufacturer of bulk ibuprofen. Ethyl also exports its bulk ibuprofen. Ethyl noted that it will soon have the capacity to produce over 2,300 metric tons of ibuprofen annually.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.
The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.
